Longitudinal analysis of clinical and biochemical outcomes during seven years of galactose supplementation in a patient with SLC35A2-CDG

Background SLC35A2-CDG is a rare X-linked congenital disorder of glycosylation caused by impaired UDP-galactose transport into the Golgi apparatus, resulting in multisystem involvement with prominent neurological manifestations. Although oral galactose supplementation has been proposed as a targeted therapy, its long-term efficacy and safety remain unclear. Methods We report a longitudinal study of a female patient with SLC35A2-CDG treated with oral D-galactose supplementation over seven years. Clinical outcomes were assessed using the Nijmegen Pediatric CDG Rating Scale (NPCRS), and glycosylation abnormalities were monitored via N-glycomics profiling. Glycosylation biomarkers associated with clinical severity were subsequently applied retrospectively to evaluate eight additional SLC35A2-CDG patients with absent or uncertain responses to galactose therapy. Results Our index patient demonstrated significantly clinical and biochemical improvements, with the NPCRS score improving from 22 to 12. Plasma N-glycan profiling showed improvement and normalization in both under-galactosylated glycans and normally formed disialylated glycans. Fractionated N-glycan analysis confirmed consistent improvement in both affinity-purified transferrin and the triple-depleted plasma fraction with IgG, transferrin and albumin removed. Strong correlations were also identified between glycosylation markers and disease severity. In contrast, seven non-responder patients showed no obvious clinical or biochemical response, while one displayed partial biochemical improvement and steady clinical course. Conclusions This study provides the first long-term evidence that galactose supplementation is effective with meaningful clinical and biochemical improvement observed in a SLC35A2-CDG patient. Glycosylation profiling may serve as a supportive tool for monitoring treatment response and guiding individualized therapy.

Authors

Institutions

Publication Details

Journal
Molecular Genetics and Metabolism Reports
Published
2026-10-16
DOI
https://doi.org/10.1016/j.ymgmr.2026.101375
Primary Topic
Lysosomal Storage Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Longitudinal analysis of clinical and biochemical outcomes during seven years of galactose supplementation in a patient with SLC35A2-CDG

Andrew C. Edmondson, Wenyue Zhang, Earnest James Paul Daniel, Yupeng Liu et al.
Molecular Genetics and Metabolism Reports
Lysosomal Storage Disorders Research
article

Longitudinal analysis of clinical and biochemical outcomes during seven years of galactose supplementation in a patient with SLC35A2-CDG

Andrew C. Edmondson, Wenyue Zhang, Earnest James Paul Daniel, Yupeng Liu, Miao He
article en

Abstract

Background SLC35A2-CDG is a rare X-linked congenital disorder of glycosylation caused by impaired UDP-galactose transport into the Golgi apparatus, resulting in multisystem involvement with prominent neurological manifestations. Although oral galactose supplementation has been proposed as a targeted therapy, its long-term efficacy and safety remain unclear. Methods We report a longitudinal study of a female patient with SLC35A2-CDG treated with oral D-galactose supplementation over seven years. Clinical outcomes were assessed using the Nijmegen Pediatric CDG Rating Scale (NPCRS), and glycosylation abnormalities were monitored via N-glycomics profiling. Glycosylation biomarkers associated with clinical severity were subsequently applied retrospectively to evaluate eight additional SLC35A2-CDG patients with absent or uncertain responses to galactose therapy. Results Our index patient demonstrated significantly clinical and biochemical improvements, with the NPCRS score improving from 22 to 12. Plasma N-glycan profiling showed improvement and normalization in both under-galactosylated glycans and normally formed disialylated glycans. Fractionated N-glycan analysis confirmed consistent improvement in both affinity-purified transferrin and the triple-depleted plasma fraction with IgG, transferrin and albumin removed. Strong correlations were also identified between glycosylation markers and disease severity. In contrast, seven non-responder patients showed no obvious clinical or biochemical response, while one displayed partial biochemical improvement and steady clinical course. Conclusions This study provides the first long-term evidence that galactose supplementation is effective with meaningful clinical and biochemical improvement observed in a SLC35A2-CDG patient. Glycosylation profiling may serve as a supportive tool for monitoring treatment response and guiding individualized therapy.

Molecular Genetics and Metabolism ReportsVol. 49
Children's Hospital of Philadelphia (US), Peking University People's Hospital (CN)
Good health and well-being
Openalex Percentile: Top 14%
Lysosomal Storage Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.